Amanda Hanson
Overview
Explore the profile of Amanda Hanson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yap T, Gainor J, Callahan M, Falchook G, Pachynski R, LoRusso P, et al.
Clin Cancer Res
. 2022 May;
28(17):3695-3708.
PMID: 35511938
Purpose: The first-in-human phase I/II ICONIC trial evaluated an investigational inducible costimulator (ICOS) agonist, vopratelimab, alone and in combination with nivolumab in patients with advanced solid tumors. Patients And Methods:...
2.
Hanson A, Elpek K, Duong E, Shallberg L, Fan M, Johnson C, et al.
PLoS One
. 2020 Sep;
15(9):e0239595.
PMID: 32970735
Immunotherapy checkpoint inhibitors, such as antibodies targeting PD-1 and CTLA-4, have demonstrated the potential of harnessing the immune system to treat cancer. However, despite encouraging results particularly with respect to...
3.
Gerhard G, Davis B, Wu X, Hanson A, Wilhelmsen D, Piras I, et al.
Biochem Biophys Rep
. 2020 Apr;
22:100753.
PMID: 32258441
We previously reported dysregulated expression of liver-derived messenger RNA (mRNA) and long noncoding RNA (lncRNA) in patients with advanced fibrosis resulting from nonalcoholic fatty liver disease (NAFLD). Here we sought...
4.
Hanson A, Piras I, Wilhelmsen D, Still C, Chu X, Petrick A, et al.
Cytokine
. 2019 Jul;
123:154789.
PMID: 31352173
CCL20 (CC chemokine ligand 20) is emerging as an important regulatory molecule in a pathway common to virus infection, alcoholic hepatitis, and non-alcoholic fatty liver disease (NAFLD) leading to the...
5.
Gerhard G, Hanson A, Wilhelmsen D, Piras I, Still C, Chu X, et al.
PLoS One
. 2019 Jul;
14(7):e0219764.
PMID: 31299062
Factors governing the development of liver fibrosis in nonalcoholic steatohepatitis (NASH) are only partially understood. We recently identified adipocyte enhancer binding protein 1 (AEBP1) as a member of a core...
6.
Hanson A, Wilhelmsen D, DiStefano J
Noncoding RNA
. 2018 Aug;
4(3).
PMID: 30134610
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions ranging from hepatic steatosis to inflammation (nonalcoholic steatohepatitis or NASH) with or without fibrosis, in the absence of significant alcohol...
7.
Drake A, Kaur M, Iliopoulou B, Phennicie R, Hanson A, Chen J
PLoS One
. 2016 Nov;
11(11):e0166280.
PMID: 27855183
T lymphocytes require signals from self-peptides and cytokines, most notably interleukins 7 and 15 (IL-7, IL-15), for survival. While mouse T cells die rapidly if IL-7 or IL-15 is withdrawn,...
8.
Curtis S, Craig W, Logue E, Vandermeer B, Hanson A, Klassen T
CMAJ
. 2015 Apr;
187(8):563-570.
PMID: 25897047
Background: Peripheral intravenous catheterization in children is challenging, and success rates vary greatly. We conducted a pragmatic randomized controlled trial to determine whether the use of ultrasound or near-infrared vascular...
9.
Henneberry R, Hanson A, Healey A, Hebert G, Ip U, Mensour M, et al.
CJEM
. 2012 May;
14(2):106-12.
PMID: 22554442
No abstract available.